Navigation Links
Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report
Date:12/4/2007

SCOTTSDALE, Ariz., Dec. 4 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for T2 diabetes therapies.

In this report, entitled "MedPredict Thought Leader Insight & Analysis: T2 Diabetes," physician experts discuss the interplay between diabetes and cardiovascular disease.

"Recent changes to the American Diabetes Association guidelines highlight the diabetic's increased risk for coronary artery disease (CAD)," according to MedPredict's President Jeff Berk. "In light of these guidelines, our Panel provides insight into unmet needs and the endocrinologist's emerging therapeutic management strategies for diabetes, CAD, metabolic syndrome and nonalcoholic steatohepatitis (NASH)."

Also discussed:

-- Incretins will dominate new launches for HbA1c lowering drugs for the

next few years. The Panel discusses the significance of targeting

DPP4, DPP8 and DPP9, and compares this class with GLP-1 agonists.

Strengths and weaknesses of new monotherapies and combination

approaches are discussed.

-- These new orals and parenterals will put pressure on established

products, including metformin, sulfonylureas and TZDs. The Panel

offers insight into how each fits into the diabetes / CAD paradigm.

-- The Panel describes why Exubera has failed commercially, and

benchmarks next-generation insulins.

-- While still very early in development, the Panel shared key insights

about the future for inhibition of SGLT.

Key products mentioned in this report: metformin, Januvia/Janumet (sitagliptin; Merck), Byetta (exenatide; Lilly/Amylin), exenatide LAR (Lilly/Amylin/Alkermes), Symlin (Amylin), pramlintide + leptin (Amylin/Amgen), Galvus (vildagliptin; Novartis), alogliptin (Takeda), saxagliptin (BMS/AZ), Redona (denagliptin; GSK), liraglutide (Novo Nordisk), Boc5 (UC Riverside / Chinese Acad. Sci.), substituted quinoxalines (Pfizer/Novo Nordisk), Actos (pioglitazone; Takeda/Lilly), Avandia (rosiglitazone; GSK), Exubera (Nektar), AIR Insulin (Lilly/Alkermes), Technosphere (Mannkind), AERx (Novo Nordisk/Aradigm), Oral-lyn (Generex/Lilly), buccal insulin (GSK).

This report can be purchased by contacting MedPredict. Members of the media may request an interview.

About MedPredict

MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Virginia Tech Review Panel Calls For Reform of Mental Health Treatment Law
2. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
3. Patient Safety Authority Board of Directors Names Infection Advisory Panel
4. Partners Rx Chief Pharmacy Officer, Richard Bullard on Panel Discussion at the Fall 2007 Managed Markets Summit (MMS) in Phoenix, AZ.
5. Billians HealthDATA GM Speaking on Dreamforce 07 Panel
6. FDA Panel Recommends Approval of SyntheMeds REPEL-CV(R) Adhesion Barrier for Pediatric Patients
7. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
8. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
9. FDA Panel Mulls Ban on Kids Cold Medicines
10. FDA Panel Weighs Ban on Kids Cold Medicines
11. FDA Panel Recommends Ban on Cold Medicines for Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... York, NY (PRWEB) , ... June 24, 2016 ... ... publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as a ... that “the most beautiful women in the world, and the most handsome men, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
Breaking Medicine Technology: